Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

Boosting protein intake helped semaglutide users to protect against some of this lean muscle loss, though. At month 3 of ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...